SCHEMBL30169110

SCHEMBL30169110

CC(C)(C)OC(=O)N[C@@H](CCC(N)=O)COc1cccc(CCCCC(=O)O)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYSLTR2 Q9NS75 1/20 0.41
CYSLTR1 Q9Y271 1/20 0.41
PPARA Q07869 3/20 0.41
PPARG P37231 2/20 0.41
ATM Q13315 1/20 0.39
CNR1 P21554 1/20 0.39
CNR2 P34972 1/20 0.39
HDAC1 Q13547 2/20 0.39
HDAC6 Q9UBN7 2/20 0.39
CSF3R Q99062 1/20 0.38
PTGIR P43119 1/20 0.38
HDAC3 O15379 1/20 0.38
HDAC4 P56524 1/20 0.38
HDAC7 Q8WUI4 1/20 0.38
HDAC2 Q92769 1/20 0.38
HDAC10 Q969S8 1/20 0.38
HDAC11 Q96DB2 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
HDAC9 Q9UKV0 1/20 0.38
HDAC5 Q9UQL6 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25383035 0.99 PPARA (0.43) CYSLTR2CYSLTR1PPARAPPARGATM
SCHEMBL22525550 0.99 PPARA (0.43) CYSLTR2CYSLTR1PPARAPPARGATM
SCHEMBL22526731 0.97 ATM (0.40) CYSLTR2CYSLTR1PPARAPPARGATM
SCHEMBL30169219 0.97 ATM (0.40) CYSLTR2CYSLTR1PPARAPPARGATM
SCHEMBL22526872 0.96 HDAC1 (0.41) PPARAPPARGATMCNR1CNR2
SCHEMBL30169343 0.93 ATM (0.43) ATMHDAC1HDAC6CSF3RHDAC3
SCHEMBL25383204 0.92 HDAC1 (0.40) PPARAPPARGATMCNR1CNR2
SCHEMBL30169228 0.92 HDAC1 (0.40) PPARAPPARGATMCNR1CNR2
SCHEMBL25383208 0.92 HDAC1 (0.40) PPARAPPARGATMCNR1CNR2
SCHEMBL22526876 0.91 HDAC1 (0.41) PPARAPPARGATMCNR1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250059221-A1 STAT DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-02-20 US disclosed
US-12077555-B2 STAT degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2024-09-03 US disclosed
US-11746120-B2 Stat degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-09-05 US disclosed
US-20230120381-A1 STAT DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-04-20 US disclosed
US-20230084113-A1 STAT DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-03-16 US disclosed
US-11485750-B1 STAT degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2022-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230084113-A1 STAT DEGRADERS AND USES THEREOF STAT4, STAT1, STAT3 CYSLTR2 1590/4885CYSLTR1 1524/4885PPARA 1856/4885
US-20230120381-A1 STAT DEGRADERS AND USES THEREOF STAT4, STAT1, STAT3 CYSLTR2 1590/4885CYSLTR1 1524/4885PPARA 1856/4885
US-12077555-B2 STAT degraders and uses thereof STAT4, STAT1, STAT3 CYSLTR2 1590/4885CYSLTR1 1524/4885PPARA 1856/4885
US-20250059221-A1 STAT DEGRADERS AND USES THEREOF STAT4, STAT1, STAT3 CYSLTR2 1590/4885CYSLTR1 1524/4885PPARA 1856/4885
US-11746120-B2 Stat degraders and uses thereof STAT4, STAT1, STAT3 CYSLTR2 1590/4885CYSLTR1 1524/4885PPARA 1856/4885
US-11485750-B1 STAT degraders and uses thereof STAT4, STAT1, STAT3 CYSLTR2 1590/4885CYSLTR1 1524/4885PPARA 1856/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.